Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

PZ0006

Sigma-Aldrich

Exemestane

≥98% (HPLC)

Sinônimo(s):

6-Methyleneandrosta-1,4-diene-3,17-dione

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C20H24O2
Número CAS:
107868-30-4
Peso molecular:
296.40
Número MDL:
MFCD00866994
Código UNSPSC:
51111800
ID de substância PubChem:
329823675
NACRES:
NA.77

Ensaio

≥98% (HPLC)

Formulário

powder

atividade óptica

[α]/D +250 to +300°, c = 1 in methanol

cor

white to off-white

solubilidade

DMSO: ≥20 mg/mL

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O

InChI

1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1

chave InChI

BFYIZQONLCFLEV-DAELLWKTSA-N

Informações sobre genes

human ... CYP19A1(1588)

Procurando produtos similares? Visita Guia de comparação de produtos

Ações bioquímicas/fisiológicas

Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.
Exemestane is a steroidal antiestrogen; aromatase inhibitor.

Características e benefícios

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictogramas

Health hazardEnvironment
GHS08,GHS09

Palavra indicadora

Danger

Frases de perigo

H360,H411

Classificações de perigo

Aquatic Chronic 2 - Repr. 1B

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
037M4720V
100M4705

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 7

1 of 7

Fulvestrant >98% (HPLC)

Sigma-Aldrich

I4409

Fulvestrant

Fadrozole hydrochloride ≥98% (HPLC)

Sigma-Aldrich

F3806

Fadrozole hydrochloride

Everolimus ≥95% (HPLC)

Sigma-Aldrich

SML2282

Everolimus

Capecitabine ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabine

Letrozole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1540

Letrozole

Raloxifene hydrochloride solid

Sigma-Aldrich

R1402

Raloxifene hydrochloride

Sunitinib malate ≥98% (HPLC)

Sigma-Aldrich

PZ0012

Sunitinib malate

John Fr Robertson et al.
The Lancet. Oncology, 14(3), 228-235 (2013-02-19)
Insulin-like growth factors (IGF-1 and IGF-2) bind to the IGF-1 receptor (IGF-1R), increasing cell proliferation and survival. Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. We tested the efficacy and safety of adding ganitumab to endocrine treatment for patients
John M S Bartlett et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(36), 4477-4484 (2012-10-10)
Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers
Elizabeth Maunsell et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(14), 1427-1436 (2014-04-09)
Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary
Willemien van de Water et al.
European journal of cancer (Oxford, England : 1990), 49(2), 297-304 (2012-09-08)
Multiple studies suggest better efficacy of chemotherapy in invasive ductal breast carcinomas (IDC) than invasive lobular breast carcinomas (ILC). However, data on efficacy of adjuvant endocrine therapy regimens and histological subtypes are sparse. This study assessed endocrine therapy efficacy in
Willemien van de Water et al.
The oncologist, 18(1), 8-13 (2012-12-25)
For postmenopausal patients with hormone-sensitive breast cancer, outcome is worse with increasing age at diagnosis. The aim of this study was to assess the incidence of breast cancer recurrence (locoregional and distant), and contralateral breast cancer by age at diagnosis.
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica